R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 13

Abstract

In this latest update we highlight a report from the European Medicines Agency on their use of realworld evidence (RWE) in decision making, RWE reporting guidance from the Canadian Agency for Drugs and Technologies in Health and highlight some new data demonstrating the value medicines for spinal muscular atrophy have brought patients.

Keywords

• canadian agency for drugs and technologies in health
• darwin eu
• electronic health records
• european medicines agency
• health technology assessment
• pharmacovigilance risk assessment committee
• real-world evidence
• regulatory
• reimbursement
• spinal muscular atrophy